Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Post archive for ‘LinkedIn’

Portola: NEJM Report on Positive Results in ANNEXA-4 Study is a Significant Positive (PTLA, Buy, $28.89)

Overview This report focuses narrowly on the New England Journal of Medicine article. If you would like a more thorough discussion on the fundamentals of Portola I suggest that you refer to two recent reports. Key Points Andexxa (andexanet) is the only approved treatment for reversal of anticoagulant effects of Factor Xa inhibitor drugs like […]

Agenus: New Blockchain Financing Instrument Could Cause a Paradigm Shift in Financing Small Biotechnology Firms (AGEN, Buy, $3.37)

Key Points Agenus is the first biotechnology company to use a new and innovative blockchain based technology for financing development of a specific product. This new technology could break the lock on financing of biotechnology firms now held by investment banking firms in the same way that Amazon has devastated most sectors of retailing.   […]

Bristol-Myers Squibb: A Highly Innovative Company Priced Like a Value Stock (BMY, Buy, $48.99)

Investment Thesis Investors have turned a thumbs down on the proposed acquisition of Celgene as there was an immediate 14% plunge in the stock price of BMY to $45. Investors are concerned about the patent situation with Celgene’s Revlimid which represents about 64% of CELG sales. The key patent protection on Revlimid expires in 2027, […]

Portola: Tidbits from Presentation at JP Morgan Healthcare Conference (PTLA, Buy, $21.96)

Investment Thesis in Brief Andexxa is the only approved product for treating severe bleeds (sometimes life threatening) caused by the Factor Xa inhibitors, principally Xarelto and Eliquis. Current standard of care (SOC) treatments have scant clinical data and are not approved by the FDA. Impotantly, Andexxa inhibits 90% of Factor Xa activity in two minutes […]

Cryoport: The Bristol-Myers Acquisition of Celgene is a Validation of my Investment Thesis for Cryoport (CYRX, Buy, $9.05)

Investment Thesis The proposed acquisition of Celgene by Bristol-Myers Squibb was generally panned by Wall Street investors and analysts as BMY stock dropped 14% on the news. The investment community is deeply concerned with the patent situation with Revlimid which accounts for over 60% of CELG revenues. There will be full blown generic entries in […]

Bristol-Myers-Squibb: Negative Market Reaction to Celgene Acquisition is a Buying Opportunity (BMY, Buy, $45.17)

Key Points Investors have turned a thumbs down on the proposed acquisition of Celgene resulting in a 14% plunge in the stock price of BMY to $45. This is because Revlimid represents about 64% of CELG sales and by 2027 or so, generic competition will erode most of its sales. The Revlimid concern was reflected […]

Portola: Approval of Gen 2 Manufacturing Process for AndexXa is a Significant Positive (PTLA, Buy, $18.75)

Portola received approval for the Prior Approval Supplement (PAS) for the Gen 2 manufacturing process for AndexXa on the PDUFA date of December 31, 2018. Management had expressed confidence in approval but in dealing with the FDA, it is never over until it’s over. AndexXa was launched in June 2018 using the inefficient Gen 1 […]

Portola Pharmaceuticals: 2019 Is All About the Sales Trajectory of AndexXa (PTLA, $15.46, Buy)

The launch of AndexXa is still in an early stage and there is considerable uncertainty about the sales trajectory in 2019 and beyond. This report focuses on issues that largely will determine sales

Comment on the Sharp Correction in Small Biopharma Stocks

Let me say a word about the stock market and the small biopharma stocks that I am recommending. The second half of 2018 and December in particular have been terrible for the market as a whole and horrendous for small biophama stocks. Many of my recommendations are down sharply from recent prices and sometimes from […]

Northwest Biotherapeutics: Non-Dilutive Financing Provides Major Boost to Investment Outlook (NWBO, $0.25, Buy)

Key Points: Monetization of a UK manufacturing facility has brought in roughly $46 million of non-dilutive cash. I estimate that payment of debt obligations over the next two years will require about $10 million leaving $36 million to fund operations. At the recent quarterly burn rate of $5 million, NWBO can fund operations through mid-2020. […]